ទំព័រដើម › មេឡាណូម៉ា › នូវយ៉ាក › New York City
ការសាកល្បងគ្លីនិកសម្រាប់ មេឡាណូម៉ា នៅក្នុង New York City, NY
ការសិក្សាចំនួន 38 សម្រាប់ មេឡាណូម៉ា កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ New York City (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Hospital, New York
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
កំពុងជ្រើសរើសដំណាក់កាល 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
កំពុងជ្រើសរើស
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Local Institution - 0170, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NYU Langone, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Hospital, New York
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
កំពុងជ្រើសរើសដំណាក់កាល 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
កំពុងជ្រើសរើស
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Project: Every Child for Younger Patients With Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- និង 2 ទៀត
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
កំពុងជ្រើសរើសដំណាក់កាល 2
- NYU Langone Health, New York
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Call for Information (Investigational Site 0031), New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- USA04-0, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Darovasertib in Primary Uveal Melanoma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
- Northwell Health Cancer Institute, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Memorial Sloan Kettering Cancer Center, New York
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Memorial Sloan Kettering Cancer Center, New York
ACTengine® IMA203 Combined With mRNA-4203
កំពុងជ្រើសរើសដំណាក់កាល 1
- Memorial Sloan Kettering Cancer Center, New York
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
កំពុងជ្រើសរើសដំណាក់កាល 2
- NYU Langone Health, New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, New York
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
កំពុងជ្រើសរើស
- Memorial Sloan Kettering Cancer Center, New York
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Weill Cornell Medicine-New York-Presbyterian Hospital, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NYU Langone Health, New York
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
កំពុងជ្រើសរើស
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Memorial Sloan-Kettering Cancer Center, New York
ការសាកល្បងសម្រាប់ មេឡាណូម៉ា នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 59
- Los Angeles, CAការសិក្សា 34
- Nashville, TNការសិក្សា 33
- Pittsburgh, PAការសិក្សា 31
- Boston, MAការសិក្សា 26
- Philadelphia, PAការសិក្សា 23
- San Francisco, CAការសិក្សា 22
- Columbus, OHការសិក្សា 21
- Durham, NCការសិក្សា 21
- Atlanta, GAការសិក្សា 21
- Salt Lake City, UTការសិក្សា 21
- St. Louis, MOការសិក្សា 21
ការសិក្សាផ្សេងទៀតនៅក្នុង New York City
- មហារីកទ្រូងការសិក្សា 136
- Non-Small Cell Lung Cancerការសិក្សា 121
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 109
- មហារីកតូចការសិក្សា 103
- មហារីកដែលរីករាលដាលការសិក្សា 93
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 78
- មហារីកស៊ុតការសិក្សា 69
- មហារីកសួតការសិក្សា 60
- ជំងឺ Multiple Myelomaការសិក្សា 60
- មហារីកតំបក់ការសិក្សា 60
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 52
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 51
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។